Letter: Effects of antiparkinsonian drugs on neuroleptic-induced extrapyramidal signs in monkeys.
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000517:prevention & control*; D001590:Benztropine / Q000627:therapeutic use; D006016:Glycolates / Q000494:pharmacology*; D006220:Haloperidol / Q000037:antagonists & inhibitors; D000882:Haplorhini; D008251:Macaca; D008297:Male; D010546:Perphenazine / Q000037:antagonists & inhibitors; D010640:Phenothiazines / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use*; D014282:Trihexyphenidyl / Q000627:therapeutic use
D000978:Antiparkinson Agents; D006016:Glycolates; D010640:Phenothiazines; D013876:Thiophenes; D001590:Benztropine; D014282:Trihexyphenidyl; D010546:Perphenazine; D006220:Haloperidol